Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Key Points

• COO Jeremy Chadwick sold 7,600 shares on March 31 at an average price of $85.38 for about $648,888, trimming his stake by 11.05% to 61,202 shares (valued ~ $5.23M).
• Kymera missed quarterly expectations with EPS of ($0.97) (vs. ($0.77) consensus) and revenue of $2.87M versus $14.8M expected, driving sharply negative margins and a year‑over‑year revenue decline.
• Analyst sentiment is mixed but leans positive overall — MarketBeat lists an average rating of Moderate Buy with an average target price of $118.90, while individual ratings range from sell to strong buy.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 7,600 shares of Kymera Therapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $85.38, for a total transaction of $648,888.00. Following the sale, the chief operating officer directly owned 61,202 shares in the company, valued at $5,225,426.76. The trade was a 11.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR traded down $0.16 during midday trading on Thursday, hitting $84.77. 114,596 shares of the company traded hands, compared to its average volume of 761,006. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $103.00. The firm has a market cap of $6.92 billion, a P/E ratio of -23.04 and a beta of 2.20. The stock has a 50-day moving average price of $81.01 and a 200 day moving average price of $71.64.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analysts' expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business's quarterly revenue was down 60.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.88) earnings per share. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KYMR shares. Weiss Ratings restated a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Oppenheimer increased their price objective on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an "outperform" rating in a report on Tuesday, December 9th. B. Riley Financial boosted their target price on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a "buy" rating in a report on Monday, December 22nd. Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They issued a "buy" rating and a $110.00 price target for the company. Finally, Wall Street Zen cut shares of Kymera Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Kymera Therapeutics has an average rating of "Moderate Buy" and an average target price of $118.90.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of KYMR. Smartleaf Asset Management LLC lifted its holdings in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock valued at $44,000 after purchasing an additional 349 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics during the 4th quarter valued at about $63,000. PNC Financial Services Group Inc. lifted its stake in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares during the period. Finally, Bessemer Group Inc. lifted its stake in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock worth $53,000 after purchasing an additional 815 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.